PubMed

Antidiabetic action of bezafibrate in a large observational database.

Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S.

Diabetes Care. 2009 Apr;32(4):547-51. Epub 2009 Jan 8.PMID: 19131462 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.

Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3.PMID: 15123532 [PubMed - indexed for MEDLINE]Related articlesFree article

Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.

Koro CE, Bowlin SJ, Weiss SR.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703.PMID: 15654719 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

Yurgin N, Secnik K, Lage MJ.

Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr.

Diabetes Care. 2005 Jan;28(1):20-6.PMID: 15616228 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.PMID: 16443869 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S.

Eur Heart J. 2005 Oct;26(19):2032-8. Epub 2005 May 4.PMID: 15872029 [PubMed - indexed for MEDLINE]Related articlesFree article

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM.

Diabetes Care. 2009 Sep;32(9):1620-5. Epub 2009 Jun 29.PMID: 19564453 [PubMed - indexed for MEDLINE]Related articles

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.PMID: 15669880 [PubMed - indexed for MEDLINE]Related articles

Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients.

Fukushima M, Taniguchi A, Sakai M, Doi K, Nagata I, Nagasaka S, Tokuyama K, Nakai Y.

Diabetes Care. 2000 Feb;23(2):259. No abstract available. PMID: 10868845 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.

Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM.

Am J Med Sci. 2008 Sep;336(3):241-7.PMID: 18794619 [PubMed - indexed for MEDLINE]Related articles

Statin use in Type 2 diabetes mellitus is associated with a delay in starting insulin.

Yee A, Majumdar SR, Simpson SH, McAlister FA, Tsuyuki RT, Johnson JA.

Diabet Med. 2004 Sep;21(9):962-7.PMID: 15317599 [PubMed - indexed for MEDLINE]Related articles

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.PMID: 16186261 [PubMed - indexed for MEDLINE]Related articlesFree article

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.PMID: 15927899 [PubMed - indexed for MEDLINE]Related articles

Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.

Jonas M, Reicher-Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, Behar S.

Am J Cardiol. 1996 Jun 15;77(15):1273-7.PMID: 8677865 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.

Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD.

Diabetes Care. 1998 Apr;21(4):641-8.PMID: 9571357 [PubMed - indexed for MEDLINE]Related articlesFree article

Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.

Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R.

Clin Ther. 2007;29 Spec No:1294-305.PMID: 18046929 [PubMed - indexed for MEDLINE]Related articles

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.

Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ.

Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):82-7.PMID: 10751747 [PubMed - indexed for MEDLINE]Related articles

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.

Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT.

Clin Ther. 2004 Sep;26(9):1400-10.PMID: 15531002 [PubMed - indexed for MEDLINE]Related articles

Underuse of cardioprotective treatment by the elderly with type 2 diabetes.

Sirois C, Moisan J, Poirier P, Grégoire JP.

Diabetes Metab. 2008 Apr;34(2):169-76.PMID: 18396087 [PubMed - indexed for MEDLINE]Related articlesFree article